The RABBIT registry is supported by a joint, unconditional grant from AbbVie, Alfasigma, Amgen, Biocon, Bristol Myers Squibb, ...

Elinzanetant is the first neurokinin-targeted therapy to demonstrate efficacy in reducing vasomotor symptoms (VMS)” — ...

Hydroxychloroquine is tied to reduced preeclampsia risk but not preterm birth risk in pregnant patients with lupus in a ...

Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

A 333-unit community, Hillcrest Apartments, will be developed directly across from Amgen’s headquarters in Thousand Oaks, ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.

MK-0616, an experimental oral medication aimed at reducing LDL cholesterol, is intended to be the first oral PCSK9 inhibitor.

For several weeks, it looked like the former South Dakota State star was going to have to find a new NFL home. Even while ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.